English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

As part of the system performance initiative of the Canadian Partnership Against Cancer, indicators measuring treatment practice patterns across the country relative to evidence-based guidelines were first published in 20101 and are updated annually. Among the treatment indicators examined is the percentage of resected stage ii and iii rectal cancer patients receiving neoadjuvant (preoperative) radiation therapy (rt), the treatment approach recommended for locally advanced rectal cancer2. Using administrative data from the provincial cancer registries, data from 2008 showed that an average of 45% of patients diagnosed with stage ii and iii rectal cancer received rt before surgical resection, ranging from 36% to 48% across provinces3. To validate those findings, and to better understand factors that may influence acceptance of and concordance with evidence-based practices, a retrospective medical chart review study was undertaken.

A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines